V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330005142 | 330002466 | 1.75 | 84 | Palliative (P) | 2016-06-04 | 2016-06-14 | FLUOROURACIL + MITOMYCIN + RT | N | N | 330021693 | UKALL XII |
| 330005143 | 330002466 | 1.71 | 75.9 | Curative (C) | 2014-03-02 | 2014-03-11 | METHOTREXATE | N | null | 330021693 | FCARBOST |
| 330005144 | 330002466 | 1.59 | 61 | Curative (C) | 2015-08-11 | 2015-08-14 | Cyclophosphamide + Docetaxel | 2 | N | 330021693 | CHOP R |
| 330005145 | 330002467 | 1.84 | 83.65 | Curative (C) | 2013-07-23 | 2013-07-24 | FLAG + Idarubicin | N | N | 330021698 | DOCETAXEL + GEMCITABINE |
| 330005146 | 330007358 | 1.6 | 67.4 | Curative (C) | 2017-07-16 | 2017-07-17 | CNS LGG 2004 03 vinc weekly+ carbo | N | N | 330021700 | AML19 TRIAL |
| 330005147 | 330007358 | 1.77 | 67 | Curative (C) | 2014-02-27 | 2014-02-27 | CETUXIMAB + CISPLATIN + FU | 02 | N | 330021700 | BEP |
| 330005148 | 330007358 | 1.66 | 76.7 | Neo-adjuvant (N) | 2017-05-10 | 2017-05-10 | Ipilimumab | 02 | N | 330021700 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 330005149 | 330002468 | null | 89.3 | Not known (9) | 2015-04-21 | 2015-04-29 | Cytarabine High Dose | null | N | 330021718 | ADE |
| 330005150 | 330002469 | null | null | Curative (C) | 2017-12-13 | 2017-12-13 | CARBOPLATIN + RT | 02 | null | 330021732 | PEMBROLIZUMAB |
| 330005151 | 330002469 | 1.68 | null | Curative (C) | null | 2013-12-10 | CISPLATIN + DOXORUBICIN + ETOPOSIDE | N | N | 330021732 | FLUOROURACIL + MITOMYCIN |
| 330005153 | 330007360 | 1.74 | 0 | Not known (9) | 2017-11-04 | 2017-11-26 | Cytarabine Low Dose | N | Y | 330021739 | CISPLATIN + DOX + ETOPOSIDE |
| 330005154 | 330007360 | 1.67 | 55 | null | 2016-08-18 | 2016-08-20 | CNS LGG 2004 03 vinc weekly+ carbo | 2 | N | 330021739 | CAPECITABINE |
| 330005155 | 330007360 | 1.56 | 16.5 | Palliative (P) | 2017-09-12 | 2017-09-13 | LIPOSOMAL DAUNORUBICIN | 02 | N | 330021739 | CAPECITABINE |
| 330005156 | 330007360 | null | 63 | Neo-adjuvant (N) | 2015-06-17 | 2015-06-18 | Cisplatin + Pemetrexed | N | N | 330021739 | CAPECITABINE + CISPLATIN |
| 330005157 | 330007360 | 0 | 73.5 | Neo-adjuvant (N) | 2017-09-23 | 2017-10-17 | ALL UKALL2011 Ind A Sht Dex (PAsp) | 02 | y | 330021739 | FLUOROURACIL + MITOMYCIN + RT |
| 330005158 | 330007360 | 0 | 102.7 | Curative (C) | 2018-04-30 | 2018-05-03 | VIDE | 01 | N | 330021739 | CISPLATIN + DOCETAXEL |
| 330005159 | 330007360 | 1.5 | 104 | Disease modification (D) | 2016-03-12 | 2016-03-15 | STS Rhabdomyosarcoma RMS 2005 IVA | N | N | 330021739 | MITOTANE |
| 330005160 | 330007360 | 1.53 | 57.3 | Curative (C) | 2015-06-13 | 2015-06-13 | EP/EMA | 02 | N | 330021739 | AML17 TRIAL |
| 330005161 | 330007360 | 0 | null | Palliative (P) | 2016-03-14 | 2016-04-10 | CYTARABINE | N | N | 330021739 | EDP + MITOTANE |
| 330005162 | 330007360 | 1.68 | 61 | Curative (C) | 2015-10-13 | 2015-10-20 | CHLVPP | 2 | N | 330021739 | CISPLATIN + DOX + ETOPOSIDE |
| 330005163 | 330007360 | 1.53 | 11.3 | Palliative (P) | 2017-11-29 | 2017-12-02 | Chlorambucil | N | Y | 330021739 | CARBOPLATIN + VINCRISTINE |
| 330005164 | 330007360 | 1.6 | 65 | Palliative (P) | 2016-10-27 | 2017-01-05 | Hydroxycarbamide | Y | N | 330021739 | DOCETAXEL + GEMCITABINE |
| 330005165 | 330002471 | 0 | 39.3 | Disease modification (D) | 2014-05-16 | 2014-05-20 | Ipilimumab | 02 | N | 330021828 | PILOT TRIAL |
| 330005166 | 330002472 | 1.86 | 89.15 | Curative (C) | 2013-11-25 | 2013-11-25 | STS Rhabdomyosarcoma RMS 2005 IVA | 2 | N | 330021830 | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE |
| 330005167 | 330002473 | 1.7 | 102 | Curative (C) | null | 2018-06-14 | FCR | null | null | 330021837 | CARBOPLATIN + RT |
| 330005168 | 330007361 | 0 | 98.1 | Palliative (P) | 2014-08-16 | 2014-09-16 | Imatinib 400mg | Y | N | 330021838 | DOCETAXEL + GEMCITABINE |
| 330005169 | 330002474 | 1.65 | 106.6 | Palliative (P) | 2014-07-11 | 2014-07-19 | Methotrexate + Folinic acid | 02 | N | 330021850 | OXALIPLATIN + MDG |
| 330005170 | 330002475 | 1.67 | null | Curative (C) | 2013-08-26 | 2013-08-27 | CAPECITABINE + GEMCITABINE | 02 | N | 330021854 | FLAG + IDARUBICIN |
| 330005171 | 330002476 | 1.6 | 40.4 | Palliative (P) | 2015-08-29 | 2015-09-01 | FLUOROURACIL + MITOMYCIN | N | N | 330021861 | CISPLATIN + FLUOROURACIL + RT |
| 330005172 | 330002477 | 1.59 | 60.4 | Palliative (P) | 2017-02-06 | 2017-02-10 | GC Int Guide Excranial GermCell JEB | N | N | 330021874 | PACLITAXEL |
| 330005173 | 330002477 | 1.68 | 84.5 | Disease modification (D) | 2017-12-27 | 2017-12-31 | FCiSt | N | N | 330021874 | BLEOMYCIN + CARBOPLATIN + CISPLATIN + VINCRISTINE |
| 330005174 | 330002478 | null | 92 | Curative (C) | 2014-09-12 | 2014-09-12 | Cytarabine Low Dose | null | null | 330021884 | ETOPOSIDE + IFOSFAMIDE |
| 330005175 | 330002479 | 1.91 | null | Curative (C) | 2018-03-27 | 2018-03-27 | POMB/ACE | null | N | 330021895 | MELPHALAN |
| 330005176 | 330002480 | 1.68 | 59.5 | Palliative (P) | 2017-10-22 | 2017-10-23 | Doxorubicin + Olaratumab | 02 | N | 330021899 | CAV |
| 330005177 | 330002480 | 1.67 | 63 | Palliative (P) | 2016-07-13 | 2016-07-20 | Gemcitabine weekly | N | N | 330021899 | TEMOZOLOMIDE |
| 330005179 | 330007364 | 1.68 | 67 | null | 2013-09-06 | 2013-09-17 | Paclitaxel 80mg/m2 day 1 8 15 | 2 | N | 330021924 | BORTEZOMIB |
| 330005180 | 330009998 | 1.53 | 73.3 | Palliative (P) | 2016-06-06 | 2016-07-01 | GC Int Guide Excranial GermCell JEB | N | N | 330021927 | CAPECITABINE + CARBOPLATIN |
| 330005181 | 330011460 | 1.68 | 33.6 | null | 2013-06-14 | 2013-06-30 | Cisplatin + Docetaxel | N | N | 330021928 | BEP |
| 330005182 | 330011460 | null | 83.8 | Curative (C) | null | 2014-09-22 | CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + IFOSFAMIDE + VINCRISTINE | null | null | 330021928 | AML16 TRIAL |
| 330005183 | 330002482 | 1.55 | null | Palliative (P) | 2017-04-23 | 2017-04-23 | GEMCITABINE | null | N | 330021951 | DOCETAXEL + GEMCITABINE |
| 330005184 | 330002483 | null | 71 | Palliative (P) | 2013-07-26 | 2013-08-01 | STS Rhabdomyosarcoma RMS 2005 IVADo | N | N | 330021970 | CAPECITABINE + STREPTOZOCIN |
| 330005185 | 330007365 | 0 | 43 | Palliative (P) | 2015-02-08 | 2015-02-15 | Methotrexate intrathecal | N | N | 330021973 | CARBOPLATIN + DOCETAXEL + FLUOROURACIL |
| 330005186 | 330002484 | 1.74 | 0 | Palliative (P) | 2015-06-18 | 2015-06-18 | Doxorubicin + Ifosfamide | 2 | N | 330021980 | VIDE |
| 330005187 | 330002485 | 1.71 | 0 | Palliative (P) | 2014-12-13 | 2014-12-17 | CAPECITABINE + OXALIPLATIN | N | N | 330021983 | FLUOROURACIL + MITOMYCIN |
| 330005188 | 330002485 | 1.76 | 99.3 | Neo-adjuvant (N) | null | 2015-07-07 | Paclitaxel 80mg/m2 day 1 8 15 | N | N | 330021983 | AML17 TRIAL |
| 330005189 | 330002486 | 1.86 | 0 | Neo-adjuvant (N) | 2015-10-15 | 2015-10-26 | Azacitidine | 02 | N | 330022002 | UKALL 2011 |
| 330005191 | 330002488 | 0 | 84 | Palliative (P) | 2014-11-29 | 2014-12-02 | BEP 3 day | N | N | 330022007 | BLEOMYCIN + CARBOPLATIN + ETOPOSIDE |
| 330005192 | 330002488 | 1.82 | 82.6 | Palliative (P) | 2015-02-01 | 2015-02-08 | IBRUTINIB | 02 | N | 330022007 | CARBOPLATIN + RT |
| 330005193 | 330002489 | 1.77 | 69.8 | Curative (C) | 2015-06-05 | 2015-07-02 | BEP 5 Day | 02 | N | 330022010 | VINORELBINE |
| 330005194 | 330002490 | 1.69 | 73 | Curative (C) | 2018-01-27 | 2018-01-28 | Chlorambucil | 02 | N | 330022016 | CISPLATIN + PEMETREXED |